Illumina Reports Preliminary Q4 2025 Results with $1.155 Billion Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: PRnewswire
- Preliminary Financial Results: Illumina reported preliminary Q4 2025 revenue of $1.155 billion, a 5% increase year-over-year, indicating stable growth potential in the genomics market, although total fiscal year revenue remained flat at $4.339 billion.
- Non-GAAP Financial Metrics: The company expects non-GAAP diluted earnings per share for FY 2025 to be between $5.42 and $5.45, reflecting effective management of operating and R&D expenses, aimed at boosting investor confidence in future profitability.
- Market Outlook: Illumina will elaborate on its financial performance and market strategy at the upcoming J.P. Morgan Healthcare Conference, which is expected to attract investor interest, particularly regarding the progress of the SomaLogic acquisition and market integration.
- Risk Factors Advisory: The company cautions that future performance may be impacted by various uncertainties, including changes in market growth rates and acquisition integration challenges, emphasizing the importance of comprehensive financial analysis for investors.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 124.12 USD with a low forecast of 40.50 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
